We are excited to announce the launch of our new webinar series called BIODATAlks, taking the format of 30-45 minute interactive conversations, and hosted by the BioData Innovation Centre team at the Wellcome Genome Campus.
News
AMSBIO reports on the positive customer feedback received for their One-Step Luciferase Assay kit recently introduced for quantitation of firefly luciferase activity in mammalian cell culture.
In recent months, the world has faced its most significant peace-time crisis, effecting all corners of the globe. Like many others, we at PIR International have adopted new working practices to adapt and to continue to support our clients and candidates, who are developing lifesaving treatments and technologies for all diseases.
Westbury, NY – May 11, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is adding high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development and help predict adverse drug reactions.
The Greenshoots Podcast by Appleyard Lees gives listeners access to insights from leading intellectual property specialists.
The bi-weekly programme delivers practical, timely guidance to innovators, inventors and IP owners and managers.
Leading IP specialists discuss the most important topics in patents, trade marks, IP litigation and IP strategy, in real time.
Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
AMSBIO has extended its COVID-19 research portfolio with the introduction of a service to provide custom lentivirus pseudotyped with spike glycoprotein from SARS-CoV-2 to help researchers identify potential targets for development of therapeutic drugs and vaccines.
Various research groups around the world have demonstrated that SARS-CoV-2 uses its spike glycoprotein S, a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry.
In response to the COVID-19 outbreak, A4P Bio Logistics has collaborated with Wren Healthcare to offer a one-stop solution for CROs, sponsors, and study sites to support the continuation of clinical trial studies through home nursing and direct-to-patient IMP and sample logistics. It has become increasingly difficult for patients to attend study sites, and our homecare solution allows studies to continue by taking the trial to the patient.
Cambridge and Inverness, UK, 30th April 2020: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focussed on bringing ODx’ system to market through TTP’s Desktop Biology service.